| 主权项 |
1. A method for testing the effectiveness of a vaccine or therapeutic composition in preventing or ameliorating re-infection with cytomegalovirus comprising:
a. administering a first guinea pig cytomegalovirus (GPCMV) to a guinea pig, b. administering a vaccine or therapeutic composition, and c. administering a second GPCMV to the guinea pig,
wherein the first GPCMV is strain ATCC/22122 and the second GPCMV is strain CIDMTR or wherein the first GPCMV is strain CIDMTR and the second GPCMV is strain ATCC/22122; andwherein(a) the CIDMTR strain is ATCC® deposit number PTA-120714;(b) the CIDMTR strain has at least 99% identity to SEQ ID NO:1;(c) the CIDMTR Strain comprises 1) a glycoprotein (GP) having greater than 94% sequence identity to GPCMV glycoprotein 131 (GP131) (SEQ ID NO:3); and 2) a GP having greater than 84% sequence identity to GPCMV glycoprotein 129 (GP129) (SEQ ID NO:2), greater than 78% sequence identity to GP74 (gO) (SEQ ID NO:4), greater than 99% sequence identity to glycoprotein 55 (gB) (SEQ ID NO:6), greater than 93% sequence identity to glycoprotein 73 (gN) (SEQ ID NO: 7), greater than 99% sequence identity to glycoprotein 115 (gL) (SEQ ID NO:8), or greater than 82% sequence identity to GP75 (gH) (SEQ ID NO:5);(d) the CIDMTR Strain comprises open reading frame gp147.1;(e) the CIDMTR Strain comprises 1) a glycoprotein (GP) having greater than 93% sequence identity to glycoprotein 73 (gN) (SEQ ID NO: 7); and 2) a GP having greater than 84% sequence identity to GPCMV glycoprotein 129 (GP129) (SEQ ID NO:2), greater than 94% sequence identity to GPCMV glycoprotein 131 (GP131) (SEQ ID NO:3), greater than 78% sequence identity to GP74 (gO) (SEQ ID NO:4), greater than 99% sequence identity to glycoprotein 55 (gB) (SEQ ID NO:6), greater than 99% sequence identity to glycoprotein 115 (gL) (SEQ ID NO:8), or greater than 82% sequence identity to GP75 (gH) (SEQ ID NO:5); or(f) the CIDMTR Strain comprises 1) a glycoprotein (GP) having greater than 99% sequence identity to glycoprotein 115 (gL) (SEQ ID NO:8); and 2) a GP having greater than 84% sequence identity to GPCMV glycoprotein 129 (GP129) (SEQ ID NO:2), greater than 94% sequence identity to GPCMV glycoprotein 131 (GP131) (SEQ ID NO:3), greater than 78% sequence identity to GP74 (gO) (SEQ ID NO:4), greater than 99% sequence identity to glycoprotein 55 (gB) (SEQ ID NO:6), greater than 93% sequence identity to glycoprotein 73 (gN) (SEQ ID NO: 7) or greater than 82% sequence identity to GP75 (gH) (SEQ ID NO:5). |
